Trump announces 100% chip tariff as Apple ups U.S. investment
LONDON - On Wednesday, LivaNova PLC (NASDAQ:LIVN), a medical technology company, reported second-quarter 2025 results that surpassed analyst expectations, with strong performance across its business segments and raised full-year guidance.
The company reported adjusted earnings per share of $1.05, significantly beating the analyst consensus of $0.87. Revenue reached $352.5 million, exceeding expectations of $332.21 million and representing a 10.7% increase on a reported basis compared to the same period last year. On an organic basis, revenue grew 10.3%.
LivaNova’s Cardiopulmonary segment led the growth with a 14.7% revenue increase to $199.3 million, driven by strong consumables demand and Essenz Perfusion System sales across all regions. The Neuromodulation segment also performed well, with revenue rising 6.2% to $151.7 million.
"LivaNova delivered another quarter of strong revenue growth, driven by continued momentum in our Cardiopulmonary business and solid Neuromodulation performance across all regions," said Vladimir Makatsaria, Chief Executive Officer of LivaNova. "Our disciplined execution contributed to meaningful operating margin expansion and strong cash generation in the second quarter."
The company raised its full-year 2025 guidance, now expecting revenue growth between 8.0% and 9.0% on a constant-currency basis and between 9.0% and 10.0% on an organic basis, up 200 basis points from previous estimates. Adjusted earnings per share guidance was increased to $3.70 to $3.80, compared to the analyst consensus of $3.65.
LivaNova also reported progress in its treatment offerings, including initiating the process with U.S. Centers for Medicare and Medicaid Services for reconsideration of national coverage for VNS Therapy for treatment-resistant depression, supported by five peer-reviewed publications from the RECOVER study.
The company generated $47.8 million in adjusted free cash flow during the quarter, demonstrating strong operational execution and financial discipline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.